Transverse myelitis associated with systemic lupus erythematosus (SLE-TM): A review article.

Autor: Jain S; Guy's and St Thomas' Hospitals NHS Trust, London, UK., Khormi A; College of Applied Medical Sciences, Prince Sattam Bin Abdulaziz University, Al-Kharj, Saudi Arabia., Sangle SR; Guy's and St Thomas' Hospitals NHS Trust, London, UK., D'Cruz DP; Guy's and St Thomas' Hospitals NHS Trust, London, UK.
Jazyk: angličtina
Zdroj: Lupus [Lupus] 2023 Aug; Vol. 32 (9), pp. 1033-1042. Date of Electronic Publication: 2023 Jul 12.
DOI: 10.1177/09612033231185612
Abstrakt: Systemic lupus erythematosus-related transverse myelitis (SLE-TM) is a rare but serious complication of SLE, which may result in significant morbidity. Its incidence is estimated between 0.5% and 1% of all SLE patients but may be the presenting feature in 30%-60% of these patients. Unfortunately, due to lack of high-quality studies, data regarding this condition remains limited. Its pathogenesis remains largely unknown and clinical presentation is variable. There are still no set guidelines regarding diagnosis, management, or monitoring and the role of autoantibodies remains controversial. In this review, we aim to summarize the available data regarding the epidemiology, pathogenesis, clinical features, management, and prognosis of this rare disease.
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje